Development of engineered pancreatic β-cell lines for cell therapy of diabetes
- 3 August 1998
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 33 (1-2) , 45-52
- https://doi.org/10.1016/s0169-409x(98)00019-2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Insulin-secreting non-islet cells are resistant to autoimmune destruction.Proceedings of the National Academy of Sciences, 1996
- Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in MiceScience, 1996
- Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patientsNature Medicine, 1996
- CTLA4-Ig PLUS BONE MARROW INDUCES LONG-TERM ALLOGRAFT SURVIVAL AND DONOR-SPECIFIC UNRESPONSIVENESS IN THE MURINE MODELTransplantation, 1996
- Gene therapy for diabetes mellitus in rats by hepatic expression of insulin.Proceedings of the National Academy of Sciences, 1995
- Oligosaccharides and Discordant XenotransplantationImmunological Reviews, 1994
- Regulated expression of human insulin in the liver of transgenic mice corrects diabetic alterationsThe FASEB Journal, 1994
- Signal transduction crosstalk in the endocrine system: pancreatic β-cells and the glucose competence conceptTrends in Biochemical Sciences, 1992
- Promotion of pancreatic islet allograft survival by intrathymic transplantation of bone marrowDiabetes, 1992
- Induction of Donor-Specific Unresponsiveness by Intrathymic Islet TransplantationScience, 1990